This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Millipore Q1 2010 Earnings Call Transcript

Third, our Bioscience division rebounded and generated impressive top line growth after a somewhat challenging year in 2009. The division reported strong laboratory instrumentation sales. And saw a sharp uptick in demand from a large North American pharmaceutical customer same time in the week last year. So I'm encouraged by the strong start and we expect the division to benefit at global economic conditions steadily improve.

Fourth, our Bioprocess business picked up right where it left off last year. The division generated exceptional growth of demand. And the biotechnology industry continues to be very robust. This performance is impressive when you consider that Bioprocess faced a challenging year-over-year comparisons and has generated 13% organic revenue growth in the first quarter of 2009.

Finally, we continue to generate attractive free cash flow as a result of improving the efficiency of working capital. We continue in making substantial improvements on working capital last year in this program, again, continue in 2010, and they show some great results. So those were the key takeaways. Let me now move into more detail about the results of the first quarter.

Financials first. So first quarter as revenues increased 14% to $463 million, excluding a 5% favorable effect from changes in currency -- foreign currency exchange rates. Organic revenue growth on the quarter was 9%. From a divisional perspective, if you exclude the effects of changes in foreign currency exchange rates, both the Bioprocess and the Bioscience division also grew 9% organically. On the bottom line, we reported $1.21 in non-GAAP earnings per share which was a 14% improvement over last year. And our free cash flow grew 12% over last year, totaling $77 million in the first quarter.

Read the rest of this transcript for free on seekingalpha.com

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
MIL $4.30 0.00%
AAPL $130.28 0.00%
FB $81.53 0.00%
GOOG $565.06 0.00%
TSLA $218.42 0.00%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs